

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



华科智能
WEALTHINK AI

WEALTHINK AI-INNOVATION CAPITAL LIMITED

華科智能投資有限公司

(Formerly known as Wealthking Investments Limited 華科資本有限公司)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1140)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 MARCH 2023

Reference is made to the annual report of Wealththink AI-Innovation Capital Limited, formerly known as Wealthking Investments Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended 31 March 2023 (the “**2023 Annual Report**”). Unless otherwise defined, terms used herein shall bear the same meanings as defined in the 2023 Annual Report.

In addition to the information provided in the 2023 Annual Report, the Board would like to provide the following further information:

MAY 2022 SUBSCRIPTION

According to the announcement of the Company dated 31 December 2021 (the “**December 2021 Announcement**”), the Company intended to use the net proceeds from the May 2022 Subscription in the following manners:

- Approximately 90% of the net proceeds would be used to capture potential investment opportunities in accordance with the Group’s investment strategy which is comprised of three pillars, namely core-holding-centered private equity, portfolio management and trading and others, with returns generated from interests, dividends and capital appreciation. The Company aimed to invest in the sectors such as medical and health, environment and industrials, technology, media and telecom as well as certain debt and other instruments.
- Approximately 10% of the net proceeds would be used for general working capital of the Group, such as staff cost and office rent.

As disclosed in the Company’s announcement dated 27 June 2022, the Board had resolved to change the use of the unutilised net proceeds of the May 2022 Subscription amounted to approximately HK\$149 million (the “**Unutilised Net Proceeds**”) from “for general working capital” to “for future investment in accordance with the Group’s investment strategy”.

As disclosed in the December 2021 Announcement and circular of the Company dated 2 March 2022, it was expected to use approximately 10% of the Net Proceeds for general working capital of the Group, such as staff cost and office rent. In view of the identification of more investment opportunities, the Directors considered that to reallocate the Unutilised Net Proceeds to capture those investment opportunities will further enhance the profitability of the Company.

Save as disclosed above, there was no other change in the use of proceeds from the May 2022 Subscription.

PARTICULARS OF MAJOR INVESTMENTS HELD BY THE GROUP

The Company wishes to provide particulars on the realised and unrealised gain or loss in relation to each major investment as follows:

As at 31 March 2023

Name of investments	Nature of business	Proportion of investee’s capital owned	Cost HK\$’000	Carrying amount HK\$’000	Net asset attributable to the Group HK\$’000	Dividend received/receivable HK\$’000	Unrealised gain/(loss) HK\$’000	Realised gain/(loss) HK\$’000	Percentage of the Group’s total assets
Investments at fair value through profit or loss									
OPIM — non-voting preference shares	Asset management	100.00%	58,000	39,900	39,900	-	2,100	-	0.35%
iCarbonX Group Limited — ordinary shares	Medical and healthcare	7.73%	1,098,790	945,849	945,849	-	(54,701)	-	8.32%
Jiedaibao Limited	Internet-based financial services	2.49%	900,389	970,520	970,520	-	15,936	-	8.54%
Hengjiameilian	Equity and property investments, and commodity trading	14.9%	450,000	447,437	447,437	-	(2,563)	-	3.94%
Dagang Holding Group Co., Limited	Manufacture and service of road construction, maintenance machinery and equipment	18.90%	781,225	452,432	452,432	-	(193,331)	(15,385)	3.98%
Ninth Eternity Asia Fund LP	Asset management	N/A	700,000	778,999	778,999	-	79,299	-	6.85%
Ninth Eternity Asia Fund II LP	Asset management	N/A	800,000	895,871	895,871	-	96,245	-	7.88%
青島萬峰時代	Asset management	N/A	803,084	808,298	808,298	-	(237)	-	7.11%
青島泰合專精特新股權投資中心	Asset management	N/A	450,232	444,859	444,859	-	3,029	-	3.91%

As at 31 March 2022

Name of investments	Nature of business	Proportion of investee's capital owned	Cost HK\$'000	Carrying amount HK\$'000	Net asset attributable to the Group HK\$'000	Dividend received/receivable HK\$'000	Unrealised gain/(loss) HK\$'000	Realised gain/(loss) HK\$'000	Percentage of the Group's total assets
Investments at fair value through profit or loss									
OPIM — non-voting preference shares	Asset management	100.00%	58,000	37,800	37,800	-	(18,200)	-	0.51%
Victorian Investment Limited Partnership — contribution	Pharmaceutical and healthcare	46.15%	234,795	142,516	142,516	-	12,208	-	1.92%
iCarbonX Group Limited — ordinary shares	Medical and healthcare	7.73%	1,098,790	1,000,551	1,000,551	-	(148,828)	-	13.45%
華建實業投資有限公司	Investment holding	12.50%	370,000	367,261	367,261	-	(32,606)	-	4.94%
Dagang Holding Group Co., Limited	Manufacture and service of road construction, maintenance machinery and equipment	19.90%	822,560	739,781	739,781	-	(131,312)	-	9.94%
Jiedaibao Limited	Internet-based financial services	2.49%	900,389	954,584	954,584	-	54,195	-	12.83%
Ninth Eternity Asia Fund LP	Asset management	N/A	700,000	699,701	699,701	-	(299)	-	9.40%
Ninth Eternity Asia Fund II LP	Asset management	N/A	800,000	799,626	799,626	-	(374)	-	10.75%

The information provided in this supplemental announcement does not affect other information contained in the 2023 Annual Report. Save as disclosed above, the contents of the 2023 Annual Report remain unchanged.

By Order of the Board
Wealthink AI-Innovation Capital Limited
Wang Qin
Chairman

Hong Kong SAR, 10 November 2023

As at the date of this announcement, the Board comprises one executive Director, namely, Dr. Liu Zhiwei; three non-executive Directors, namely Dr. Wang Qin, Dr. Fu Weigang and Dr. Wang Shibin; and three independent non-executive Directors, namely, Mr. Chen Yuming, Mr. Yan Xiaotian and Mr. Zhao Kai.